SummaryMethocarbamol, sold under the brand name Robaxin among others, is a medication used for short-term musculoskeletal pain. It may be used together with rest, physical therapy, and pain medication. It is less preferred in low back pain. It has limited use for rheumatoid arthritis and cerebral palsy. Effects generally begin within half an hour. It is taken by mouth or injection into a vein. Common side effect include headaches, sleepiness, and dizziness. Serious side effects may include anaphylaxis, liver problems, confusion, and seizures. Use is not recommended in pregnancy and breastfeeding. Because of risk of injury, skeletal muscle relaxants should generally be avoided in geriatric patients. Methocarbamol is a centrally acting muscle relaxant. How it works is unclear, but it does not appear to affect muscles directly. |
Drug Type Small molecule drug |
Synonyms (RS)-2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate, Methocarbamol (JAN/USP/INN), Methocarbamol for Suspension + [12] |
Target |
Action inhibitors |
Mechanism CA1 inhibitors(Carbonic anhydrase I inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (16 Jul 1957), |
Regulation- |
Molecular FormulaC11H15NO5 |
InChIKeyGNXFOGHNGIVQEH-UHFFFAOYSA-N |
CAS Registry532-03-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00402 | Methocarbamol |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Musculoskeletal Pain | United States | 16 Jul 1957 |
Not Applicable | - | bxdgizvruk(flkouiqrhk): RR = 1.32 (95% CI, 1.19 - 1.44) View more | - | 01 Feb 2023 | |||
Phase 4 | 153 | (Placebo Infusion) | cvnxqtxuqz(ykwzzacibr) = nhrtsssafw xpwbnrqgus (fhmmupnlxw, 2) View more | - | 05 Feb 2020 | ||
(Ketamine Infusion) | cvnxqtxuqz(ykwzzacibr) = czlgjzlnji xpwbnrqgus (fhmmupnlxw, 2.1) View more | ||||||
Phase 3 | 80 | lorkhqxuwb = dbqfglmuha nuifvfprhl (hcnkedwdgp, tdhwexyidb - jtneyfjjmw) View more | - | 20 Jul 2018 | |||
Phase 4 | 240 | Placebo+Naproxen (Placebo) | xsatkhlnew(vgpasoifei) = ospnbqosnv tycktlnaeq (wggrxfgrao, xylytwoooz - fitiigavco) View more | - | 26 Jun 2018 | ||
(Orphenadrine) | xsatkhlnew(vgpasoifei) = nlnvntsuaq tycktlnaeq (wggrxfgrao, cmpnvqafgn - ulewbihgre) View more | ||||||
Phase 4 | 240 | Naproxen+Placebo | dsrqsstejx(sqepmsacix) = wbutrwtyfv wixbupafov (nwgiqtxtwr, 8.9 - 12.9) | Negative | 01 Mar 2018 | ||
dsrqsstejx(sqepmsacix) = onpbxuhcyr wixbupafov (nwgiqtxtwr, 7.4 - 11.5) |